Nasonex Adverse Reactions

Clinical Trials Experience: Treatment-related local adverse events reported in clinical studies with Mometasone furoate (NASONEX*) Aqueous Nasal Spray include headache (8%), epistaxis (i.e., frank bleeding, blood-tinged mucus, and blood flecks (8%), pharyngitis (4%), nasal burning (2%), nasal irritation (2%), and nasal ulceration (1%), which are typically observed with use of a corticosteroid nasal spray. Epistaxis was generally self-limiting and mild in severity, and occurred at a higher incidence compared to placebo (5%), but at a comparable or lower incidence compared to the active control nasal corticosteroids studied (up to 15%).
In patients treated for acute rhinosinusitis, the overall incidence of adverse events was comparable to placebo and similar to that observed for patients with allergic rhinitis.
Nasal Polyposis: In patients treated for nasal polyposis, the overall incidence of adverse events was comparable to placebo and similar to that observed for patients with allergic rhinitis.
Post-Market Experience: The following additional adverse reactions have been reported in post-marketing use with Mometasone furoate (NASONEX): vision blurred.